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ACUTE MYOCARDIAL INFARCTION

When Is Door-to-Balloon Time Critical?
Analysis From the HORIZONS-AMI (Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial Infarction) and
CADILLAC (Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications) Trials
Bruce R. Brodie, MD,* Bernard J. Gersh, MB, CHB, DPHIL,† Thomas Stuckey, MD,*
Bernhard Witzenbichler, MD,‡ Giulio Guagliumi, MD,§ Jan Z. Peruga, MD,储 Dariusz Dudek, MD,¶
Cindy L. Grines, MD,# David Cox, MD,** Helen Parise, SCD,†† Abhiram Prasad, MD,†
Alexandra J. Lansky, MD,†† Roxana Mehran, MD,†† Gregg W. Stone, MD††
Greensboro, North Carolina; Rochester, Minnesota; Berlin, Germany; Bergamo, Italy;
Lodz and Krakow, Poland; Royal Oak, Michigan; Allentown, Pennsylvania; and New York, New York
Objectives

Our objective was to evaluate the impact of door-to-balloon time (DBT) on mortality depending on clinical risk
and time to presentation.

Background

DBT affects the mortality rate in ST-segment elevation myocardial infarction treated with primary percutaneous
coronary intervention, but the impact may vary across subgroups.

Methods

The CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) and
HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trials
evaluated stent and antithrombotic therapy in patients undergoing primary percutaneous coronary intervention.
We studied the impact of DBT on mortality in 4,548 patients based on time to presentation and clinical risk.

Results

The 1-year mortality rate was lower in patients with short versus long DBT (ⱕ90 min vs. ⬎90 min, 3.1% vs.
4.3%, p ⫽ 0.045). Short DBTs were associated with a lower mortality rate in patients with early presentation
(ⱕ90 min: 1.9% vs. 3.8%, p ⫽ 0.029) but not those with later presentation (⬎90 min: 4.0% vs. 4.6%, p ⫽ 0.47).
Short DBTs showed similar trends for a lower mortality rate in high-risk (5.7% vs. 7.4%, p ⫽ 0.12) and low-risk
(1.1% vs. 1.6%, p ⫽ 0.25) patients. Short DBTs had similar relative risk reductions in patients with early presentation in high-risk (3.7% vs. 7.0%, p ⫽ 0.08) and low-risk (0.8% vs. 1.5%, p ⫽ 0.32) patients, although the absolute benefit was greatest in high-risk patients.

Conclusions

Short DBTs (ⱕ90 min) are associated with a lower mortality rate in patients with early presentation but have
less impact on the mortality rate in patients presenting later. The absolute mortality rate reduction with short
DBT is greatest in high-risk patients presenting early. These data may be helpful in designing triage strategies
for reperfusion therapy in patients presenting to non–percutaneous coronary intervention hospitals. (J Am Coll
Cardiol 2010;56:407–13) © 2010 by the American College of Cardiology Foundation

Short door-to-balloon (DBT) times are associated with
reduced mortality in patients with ST-segment elevation
myocardial infarction (STEMI) treated with primary per-

cutaneous coronary intervention (PCI), but the importance
of DBT may differ across subgroups (1–3). Previous studies
suggested that delays in DBT may affect the mortality rate
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most in patients presenting early
after the onset of symptoms and
in patients at high clinical risk,
DBT ⴝ door-to-balloon time
but the data are limited and conPCI ⴝ percutaneous
flicting (2,3). Improved undercoronary intervention
standing of how delays in DBT
STEMI ⴝ ST-segment
affect the mortality rate in subelevation myocardial
groups may help in triaging
infarction
STEMI patients presenting at
TIMI ⴝ Thrombolysis In
Myocardial Infarction
non-PCI hospitals.
The purpose of this study was to
evaluate the impact of delays in
DBT on mortality in patients with early versus late presentation and in patients with high and low clinical risk from the
CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) and
HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trials
(4,5).
Abbreviations
and Acronyms

Methods

Baseline
by Variables
Time to Presentation
Table 2 Variables
Baseline
by Time to Presentation
Time to Presentation

Door-to-Balloon Time
<90 min
(n ⴝ 1,611)

>90 min
(n ⴝ 2,937)

p Value

Clinical variables
Age, yrs

60.1 (11.8)

60.3 (12.0)

0.62

Age ⱖ65 yrs

35.1%

35.8%

0.64

Age ⱖ75 yrs

12.5%

13.5%

0.35

Female

22.7%

26.1%

0.011

Diabetes

14.6%

17.0%

0.032

Prior infarction

10.1%

12.6%

0.012

Anterior infarction

40.1%

40.0%

0.92

Killip class II to IV

8.8%

10.1%

0.16

Weight, kg

81.6 (15.4)

82.6 (16.4)

0.058

Weight ⬍67 kg

15.9%

15.3%

0.58

Time to presentation ⱕ90 min

41.1%

42.0%

0.55

1.7 (1.6)

1.8 (1.7)

0.19

Left anterior descending

40.1%

40.0%

0.98

Circumflex

16.2%

18.6%

0.042

Right coronary artery

46.9%

44.4%

0.10

0.3%

0.1%

0.23

17.5%

19.8%

0.061

58.1 (12.7)

57.8 (12.8)

0.62

TIMI risk score
Angiographic variables
Infarct artery location

Left main
3-vessel disease
Index LVEF, %
Index LVEF ⬍40%
TIMI flow grade 2 to 3 pre-PCI

9.5%

9.7%

0.31

27.9%

37.7%

⬍0.0001

Values are mean (SD) or percent.
LVEF ⫽ left ventricular ejection fraction; PCI ⫽ percutaneous coronary infarction; TIMI ⫽
Thrombolysis In Myocardial Infarction.

p Value

58.4 (11.7)

61.6 (11.9)

⬍0.0001

Age ⱖ65 yrs

29.6%

40.2%

⬍0.0001

Age ⱖ75 yrs

10.1%

15.2%

⬍0.0001

Female

21.1%

27.2%

⬍0.0001

Diabetes

12.9%

18.3%

⬍0.0001

Prior infarction

12.8%

11.0%

0.064

Anterior infarction

41.6%

38.9%

0.07

Killip class II to IV

9.1%

10.0%

0.32

83.4 (16.3)

81.5 (15.9)

⬍0.0001

Age, yrs

Weight, kg
Weight ⬍67 kg

14.1%

16.6%

0.02

TIMI risk score

1.6 (1.6)

1.9 (1.7)

⬍0.0001

Left anterior descending

41.4%

39.1%

0.11

Circumflex

16.3%

18.8%

0.029

Right coronary artery

45.2%

45.2%

0.97

0.1%

0.2%

0.34

16.5%

21.2%

⬍0.0001

58.2 (12.6)

57.9 (12.7)

0.46

8.5%

9.4%

0.44

35.2%

33.6%

0.25

Angiographic variables
Infarct artery location

3-vessel disease

Baseline
by Variables
Door-to-Balloon
Time
Table 1 Variables
Baseline
by Door-to-Balloon
Time

>90 min
(n ⴝ 2,700)

Clinical variables

Left main

Study population. The CADILLAC trial evaluated abciximab and coronary stenting and the HORIZONS-AMI
trial evaluated bivalirudin and drug-eluting stents in
STEMI patients undergoing primary PCI (4,5). The current study population included all patients randomized in

<90 min
(n ⴝ 1,917)

Index LVEF, %
Index LVEF ⬍40%
TIMI flow grade 2 to 3 pre-PCI
Values are mean (SD) or percentage.
Abbreviations as in Table 1.

these trials who underwent primary PCI and had DBT data
available (n ⫽ 4,548).
Definitions. DBT was the time from hospital arrival until
balloon inflation. Time to presentation was the time from
symptom onset until arrival at the first hospital. Clinical risk
was assessed using a modified Thromobolysis In Myocardial
Infarction (TIMI) risk score (6). Selected variables were
assigned points weighted as follows: age 75 years and older
(3 points), age 65 years and older (2 points), Killip class II
to IV (2 points), anterior infarction (1 point), diabetes (1
point), weight ⬍67 kg (1 point), and these were summed for
each patient to give a modified TIMI risk score.
Statistical analyses. Baseline categorical variables were
compared using chi-square testing, and continuous variables
were compared using t tests. Mortality rates at 1 year were
determined by Kaplan-Meier estimates, and comparisons
between categories of DBT were performed with univariate
and multivariate Cox regression analyses. In the multivariate
Cox regression models, all clinical variables in Tables 1 and 2
were entered into the models.

Results
Median time to presentation was 112 min (interquartile
range 60 to 205 min) and median DBT, including both
transferred and nontransferred patients, was 107 min (interquartile range 79 to 146 min).
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Cut-Point
for Analyses
DBT, Time
Presentation,
and TIMI Risk
Score
Table 3 Analyses
Cut-Point
fortoDBT,
Time to Presentation,
and
TIMI Risk Score
1-Year Mortality (%)*
DBT cut points

Short DBT

Hazard Ratio†

95% CI

p Value

Long DBT

60 min

3.0

4.0

0.75

0.45–1.22

0.25

90 min

3.1

4.3

0.72

0.52–0.99

0.045

3.7

4.1

0.87

0.65–1.16

0.35

DBT ⱕ90 min

DBT ⬎90 min

120 min
Time to presentation cut points
ⱕ60 min (n ⫽ 1,122)

2.3

3.3

0.68

0.31–1.52

0.34

⬎60 min (n – 3,327)

3.4

4.6

0.73

0.51–1.05

0.09

ⱕ90 min (n ⫽ 1,853)

1.9

3.8

0.49

0.26–0.93

0.029

⬎90 min (n ⫽ 2,596)

4.0

4.6

0.86

0.58–1.28

0.47

ⱕ120 min (n ⫽ 2,472)

2.4

3.5

0.69

0.42–1.14

0.15

⬎120 min (n ⫽ 1,977)

4.0

5.2

0.76

0.49–1.19

0.24

Modified TIMI risk cut points

DBT ⱕ90 min

DBT ⬎90 min

TIMI risk score ⬍2 (n ⫽ 2,402)

1.1

1.6

0.64

0.30–1.37

0.25

TIMI risk score ⱖ2 (n ⫽ 2,047)

5.7

7.4

0.75

0.51–1.02

0.12

TIMI risk score ⬍3 (n ⫽ 3,067)

1.4

2.1

0.65

0.36–1.18

0.16

TIMI risk score ⱖ3 (n ⫽ 1,382)

7.2

9.0

0.78

0.52–1.14

0.20

TIMI risk score ⬍4 (n ⫽ 3,738)

2.0

2.5

0.73

0.46–1.15

0.17

TIMI risk score ⱖ4 (n ⫽ 711)

9.7

13.1

0.75

0.47–1.19

0.22

*1-year mortalities are Kaplan-Meier estimates. †Hazard ratios are unadjusted and compare mortality with short versus long door-to-balloon times (DBTs).
CI ⫽ confidence interval; other abbreviations as in Table 1.

Baseline variables by DBT and time to presentation.
The frequency of female sex, diabetes, and previous
infarction was higher in patients with long versus short
DBT (Table 1).
Patients with late versus early time to presentation were
older, more often female, and more often diabetic; weighed
less; and had a higher modified TIMI risk score (Table 2).
Cut-point analyses. On the basis of previous experiences
(1–3), comparisons of mortality with short versus long DBT
were assessed at cut points of 60, 90, and 120 min. A cut

Figure 1

point of 90 min gave the lowest hazard ratio (HR) for
mortality comparing short and long DBTs (Table 3).
Comparisons of mortality by DBT in patients with early
versus late time to presentation were assessed at time to
presentation cut points of 60, 90, and 120 min (2,3). A cut
point of 90 min resulted in the greatest difference in HRs
for mortality rate with short versus long DBTs between
patients with early and late presentation (Table 3).
Comparisons of mortality by DBT in patients at low and
high clinical risk were assessed at TIMI risk score cut points

DBT and 1-Year Mortality Rate

Kaplan-Meier estimates for mortality rate in ST-segment elevation myocardial infarction patients with a door-to-balloon time (DBT) of ⱕ90 min versus ⬎90 min.
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of 2, 3, and 4. All cut points demonstrated similar HRs for
high- and low-risk groups (Table 3).
Impact of DBT on 1-year mortality by time to presentation
and TIMI risk score. In the entire cohort, short DBTs
(ⱕ90 min) were associated with significantly lower mortality
rates (3.1% vs. 4.3%, HR: 0.72, 95% confidence interval [CI]:
0.52 to 0.99, p ⫽ 0.045) (Table 3, Fig. 1). After adjusting for
differences in baseline variables, study differences, and treatment assignment, the differences were not quite significant
(HR: 0.72, 95% CI: 0.52 to 1.01, p ⫽ 0.058).

Figure 2

JACC Vol. 56, No. 5, 2010
July 27, 2010:407–13

In patients with early time to presentation (ⱕ90 min),
short DBTs (ⱕ90 min) were associated with lower mortality rate (1.9% vs. 3.8%, HR: 0.49, 95% CI: 0.26 to 0.93,
p ⫽ 0.029), whereas in patients with late time to presentation (⬎90 min), the DBT had no significant impact on the
mortality rate (4.0% vs. 4.6%, HR: 0.86, 95% CI: 0.58 to 1.28,
p ⫽ 0.47) (p value for interaction ⫽ 0.14) (Table 3, Fig. 2).
The impact of short DBTs on patients with early presentation
remained significant after adjusting for differences in baseline
variables (HR: 0.51, 95% CI: 0.26 to 0.98, p ⫽ 0.044).

DBT and 1-Year Mortality Rate in Early and Late Presenters

Kaplan-Meier estimates for mortality comparing door-to-balloon time (DBT) of ⱕ90 min versus ⬎90 min
in patients with time to presentation ⱕ90 min (A) and in patients with time to presentation ⬎90 min (B).
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DBT and 1-Year Mortality Rate in Low- and High-Risk Patients

Kaplan-Meier estimates for mortality comparing door-to-balloon time (DBT) of ⱕ90 min versus ⬎90 min in patients at low risk
(modified Thrombolysis In Myocardial Infarction [TIMI] risk score ⬍2) (A) and in patients at high risk (modified TIMI risk score ⱖ2) (B).

The HRs of short and long DBTs for 1-year mortality
rate were similar in high- and low-risk patients (modified
TIMI risk score ⱖ2 vs. ⬍2) (p value for interaction ⫽ 0.71)
(Table 3, Fig. 3). However, the absolute reduction in
mortality rate with short DBTs was greater in high-risk
than low-risk patients (1.7% vs. 0.5%) (Table 3).
In patients presenting early (ⱕ90 min), the HRs for
mortality rate in patients with short versus long DBTs
were identical for high- versus low-risk patients, but the
absolute mortality rate differences were greater in high-

risk patients (3.3% vs. 0.7%) (Table 4, Fig. 4). In patients
presenting late (⬎90 min), mortality was similar with
short and long DBTs in both high- and low-risk patients
(Table 4).
Discussion
The major finding of this study is that short DBTs (⬍90 min)
are associated with a lower 1-year mortality rate in patients
presenting early after the onset of symptoms but appear to have
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DBT and 1-Year Mortality Rate in Low- and High-Risk Patients Presenting Early

Kaplan-Meier estimates for mortality comparing DBT of ⱕ90 min versus ⬎90 min in patients with time to presentation ⱕ90 min in
patients at low risk (modified TIMI risk score ⬍2) (A) and in patients at high risk (modified TIMI risk score ⱖ2) (B). Abbreviations as in Figure 3.

less impact on the mortality rate in patients presenting later. A
second finding of our study is that short DBTs are associated
with similar relative reductions in mortality rate in low- and
high-risk patients, although the absolute reduction in mortality
rate is greatest in high-risk patients.
These data are consistent with the mechanism of
benefit of reperfusion therapy described by Gersh et al.
(7), which states that the greatest benefit of reperfusion
occurs when reperfusion is achieved within the first 2 to
3 h, during which time incremental delays result in

considerable loss of myocardial salvage and survival. After
2 to 3 h, incremental delays have much less impact on
outcomes. Accordingly, short DBTs should be most
beneficial in patients presenting early after the onset of
symptoms when reperfusion can be achieved within the
time window of maximal benefit.
Data regarding this are conflicting. A large single-center
study found improved survival with short DBTs in patients
presenting early but not in patients presenting later (2). In
contrast, a large registry found that short DBTs were
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1-Year
Rate
by DBT,Rate
TimebytoDBT,
Presentation,
and TIMI Risk
Score
TableMortality
4
1-Year
Mortality
Time to Presentation,
and
TIMI Risk Score
1-Year Mortality (%)*
DBT <90 min

DBT >90 min

Hazard Ratio†

95% CI

p Value

Time to presentation ⱕ90 min
TIMI risk score ⬍2 (n ⫽ 1,102)

0.8

1.5

0.52

0.14–1.89

0.32

TIMI risk score ⱖ2 (n ⫽ 751)

3.7

7.0

0.52

0.24–1.08

0.08

Time to presentation ⬎90 min
TIMI risk score ⬍2 (n ⫽ 1,300)

1.3

1.7

0.76

0.29–2.00

0.58

TIMI risk score ⱖ2 (n ⫽ 1,296)

6.8

7.6

0.88

0.57–.35

0.57

*1-year mortalities are Kaplan-Meier estimates. †Hazard ratios are unadjusted and compare mortality with short versus long DBTs.
Abbreviations as in Tables 1 and 3.

associated with a lower mortality rate in patients with both
early and late presentation (3). Hidden biases in registries
for patients with long DBTs to have higher mortality may
explain the differences between the registry data and the
present study.
Clinical implications. Pinto et al. (8) found that the
PCI-related delay at which primary PCI loses its advantage
over fibrinolytic therapy was shorter in patients presenting
early versus later and in anterior versus nonanterior infarction. These data and our data suggest that patients presenting early (and patients at high clinical risk) may benefit from
alternative reperfusion strategies such as fibrinolysis or
facilitated PCI. Facilitated PCI strategies have not yet
shown any advantage over primary PCI, but a retrospective
analysis of the FINESSE (Facilitated INtervention with
Enhanced Reperfusion Speed to Stop Events) trial found
that high-risk patients presenting early at spoke hospitals
had better outcomes with facilitated PCI compared with
primary PCI (9 –11). It remains to be proven whether
facilitated PCI might be beneficial in high-risk STEMI
patients presenting early after the onset of symptoms.
Study limitations. This is an observational, post hoc analysis of data from 2 randomized trials. We believe that this is
a representative group of the overall STEMI population,
but we do not have data on patients who were screened but
not enrolled to document this. Also, exclusion of patients
because of missing DBT data could potentially affect our
results.
In analyzing numerous cut points, there is the potential
for false-positive results. However, our cut points were
based on clinical considerations, which should minimize
this error.
Although this is the largest randomized primary PCI
database evaluating DBT, the power to detect differences in
mortality rate in subgroups is limited. This may be the
reason why the adjusted differences in mortality rate between short and long DBTs and the interaction between
time to presentation and DBT on mortality rate were not
quite significant.

Reprint requests and correspondence: Dr. Bruce R. Brodie, 313
Meadowbrook Terrace, Greensboro, North Carolina 27408. E-mail:
bbrodie@triad.rr.com.
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